Catalent (CTLT)
(Delayed Data from NYSE)
$55.52 USD
-0.28 (-0.50%)
Updated May 14, 2024 04:00 PM ET
After-Market: $55.50 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.52 USD
-0.28 (-0.50%)
Updated May 14, 2024 04:00 PM ET
After-Market: $55.50 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Zacks News
Looking for a Growth Stock? Why It is Time to Focus on Catalent (CTLT)
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).
Pacira (PCRX) Gets European Commission Approval for Exparel
by Zacks Equity Research
The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.
Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU
by Zacks Equity Research
Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.
Zoetis (ZTS) Librela Gets Marketing Authorization in Europe
by Zacks Equity Research
Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.
Catalent (CTLT) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 13.16% and 4.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.
AcelRx (ACRX) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
AcelRx (ACRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session
by Zacks Equity Research
Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Ironwood to End IW-3718 Development After Study Failure
by Zacks Equity Research
Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.
Endo (ENDP) Surges: Stock Moves 8.4% Higher
by Zacks Equity Research
Endo (ENDP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Revolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in Session
by Zacks Equity Research
Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Spectrum Pharmaceuticals (SPPI) Jumps: Stock Rises 7%
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Vaxart (VXRT) Surges: Stock Moves 8.1% Higher
by Zacks Equity Research
Vaxart (VXRT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Champions Oncology (CSBR) Catches Eye: Stock Jumps 9.2%
by Zacks Equity Research
Champions Oncology (CSBR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Etsy, Generac, Catalent, Fortune Brands Home & Security and Wayfair
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Etsy, Generac, Catalent, Fortune Brands Home & Security and Wayfair
Sage Therapeutics (SAGE) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
6 Top Stocks That Turned Large Cap From Mid Cap Amid Pandemic
by Nalak Das
In the due course of the S&P 400 Index's fabulous performance in the past five months, several mid-cap stocks have become large caps. We have selected six of these that carry a favorable Zacks Rank.
New Strong Buy Stocks For September 11th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Exelixis Inks a Couple of Deals to Develop Novel ADCs for Cancer
by Zacks Equity Research
Exelixis (EXEL) signs a collaboration agreement with private biotech NBE-Therapeutics for developing novel antibody-drug conjugates (ADCS) to address cancer. It also inks a similar deal with Catalent.
Merck Announces Detailed Data on Late-Stage Cough Candidate
by Zacks Equity Research
Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.
Radius Completes Enrollment in Phase III Osteoporosis Study
by Zacks Equity Research
Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Is Catalent (CTLT) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).
Is Catalent (CTLT) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).
High-Flying Equities Stumble, but Remain Near All-Time Highs
by David Borun
Technology stocks slip modestly as investors reassess valuations after an historic rally off March lows.